American Diabetes Association

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

Retrieved on: 
Thursday, May 2, 2024
American Diabetes Association, Abstract, Diabetes, Doctor of Philosophy, TTP, Longevity, Medical device

Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.

Key Points: 
  • Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.
  • The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention, and care.
  • This annual meeting provides researchers and health care professionals with the unique opportunity to share ideas and learn about cutting edge technologies and breakthroughs in diabetes research and diabetes-related conditions.
  • “We look forward to presenting two posters discussing the preclinical animal studies and the sensor longevity simulation modeling for our Continuous Blood Glucose Monitor (CBGM)” said Paul V. Goode, PhD, CEO of Glucotrack.

Eversense® CGM System Receives iCGM Designation by the US FDA

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Health, FDA, Diabetes, Medical Devices, Consumer Electronics, Health Technology, Technology, Consensus, American Diabetes Association, Safety, Physician, De novo, CGM, Partnership, Doctor of Philosophy, Patient, Practitioner, AID, Medical device

iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.

Key Points: 
  • iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
  • “The rigorous data requirements for this FDA designation highlight our team's advanced engineering expertise in developing a CGM that meets high standards.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.

Eversense® CGM System Receives iCGM Designation by the US FDA

Retrieved on: 
Tuesday, April 30, 2024
Health, FDA, Diabetes, Medical Devices, Health Technology, Technology, Apps, Applications, Mobile, Wireless, Consensus, American Diabetes Association, Safety, Physician, De novo, CGM, Partnership, Doctor of Philosophy, Patient, Practitioner, AID, Medical device

iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.

Key Points: 
  • iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
  • “The rigorous data requirements for this FDA designation highlight our team's advanced engineering expertise in developing a CGM that meets high standards.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Retrieved on: 
Tuesday, April 30, 2024
Contract research organization, American Diabetes Association, GAN, Part, Congress, EASL, Gubra, OXM, Weight loss, GCGR, GLP1R, GPR119, Obesity, SAD, Glucagon-like peptide-1 receptor, MASH, Pharmaceutical industry

"We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • "We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
  • DA-1726 has consistently shown, in our preclinical data, to sustain weight loss in diet-induced obese models by decreasing food consumption and boosting energy expenditure.
  • Both programs are progressing well, and we have been able to significantly accelerate the clinical timelines for DA-1726.
  • A member of the Dong-A ST Research Center will present pre-clinical data on DA-1726 in a poster presentation at this scientific session in Orlando, FL.

Dr. Mauricio Gonzalez Selects Fastlane as Agency of Record

Retrieved on: 
Thursday, April 18, 2024
American Diabetes Association, Health, Heart, Diabetes, Exercise, AARP, Hypertension, Quality of life, Organization, American Heart Association

NEW YORK, April 18, 2024 /PRNewswire-PRWeb/ -- Dr. Mauricio Gonzalez, best known as Dr. Mau, an award-winning, triple board-certified physician in internal, emergency, and obesity medicine based in New York City, has selected Fastlane as the agency of record (AOR) for his rapidly-growing, health education business. Driven by a mutual goal of strengthening Dr. Mau's social reach and impact and further developing strategic partnerships, this alliance is poised to advance his brand profile within the healthcare and wellness industries.

Key Points: 
  • "I am genuinely excited to partner with Fastlane to amplify my mission and message and reach a broader audience.
  • A Fastlane specialty is identifying untapped opportunities within specific market segments and devising targeted strategies to produce positive business outcomes.
  • "Fastlane is honored to partner with such a high profile and well-respected healthcare practitioner and thought leader like Dr. Mau," said Chris Faust, Founder and CEO of Fastlane.
  • Fastlane and Dr. Mau's collaboration marks a significant step towards bridging the information gap and advancing communications in the healthcare industry.

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Retrieved on: 
Tuesday, April 2, 2024
Patient, MIB, ARI, Therapy, AAO, Research, Surgeon, Thomas Jefferson University, German Research Foundation, Chairperson, American Diabetes Association, Macular degeneration, SAB, FACS, Food, Cornell University, Empire, University, Castle Connolly Medical, Laborie (company), Publication, Emerita, AMD, FDA, Cochrane (organisation), Moorfields Eye Hospital, American Academy, Most, Consultant, Physician, Royal college, Diabetic retinopathy, Commander, Pharmaceutical industry

WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901.

Key Points: 
  • “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion.
  • Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad.
  • FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
  • He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA.

Beyond Meat® Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart Association’s Heart-Check Program and the American Diabetes Association’s Better Choices for Life Program

Retrieved on: 
Thursday, March 28, 2024
American Heart Association, Health, LDL, Certification, Cardiovascular disease, Taste, BYND, Nutrition, TMAO, Nutrient, Diabetes, American Journal, American Cancer Society, Stroke, Crumble, Beyond Meat, Sodium, Food, Death, Risk, Breakfast, Diet, American Diabetes Association, Beyond, Reference Daily Intake, Lunch, Cholesterol, American Heart, Dietary supplement

Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.

Key Points: 
  • Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.
  • Beyond Crumbles’ strong nutritional profile, coupled with its simple and clean ingredient list, earned the product certification by the American Heart Association’s Heart-Check program and the American Diabetes Association’s Better Choices for Life program,” said Beyond Meat Founder and CEO Ethan Brown.
  • As part of Beyond Meat’s commitment to innovating for human health, this announcement follows Beyond Steak’s earlier certifications by the American Heart Association and the American Diabetes Association .
  • With 1.2 million Americans diagnosed with diabetes every year , the Better Choices for Life Program uses the American Diabetes Association’s evidence-based guidelines to help consumers make informed choices about the foods they purchase.

BRG Communications Receives Second-Consecutive Best Boutique Agency Win at 25th Annual PRWeek Awards

Retrieved on: 
Tuesday, March 26, 2024
National Sleep Foundation, Education, Heel, American Diabetes Association, American College, PRWeek, American Cleaning Institute, BRG, Multimedia, PRSA, Nursing

ALEXANDRIA, Va., March 26, 2024 /PRNewswire/ -- For the second year in a row, BRG Communications (BRG) earned top recognition from PRWeek as Outstanding Boutique Agency.

Key Points: 
  • ALEXANDRIA, Va., March 26, 2024 /PRNewswire/ -- For the second year in a row, BRG Communications (BRG) earned top recognition from PRWeek as Outstanding Boutique Agency.
  • Celebrated as one of the most prestigious awards in the communications industry, BRG was honored for agency growth, client and staff retention as well as innovation and training.
  • During the ceremony, PRWeek highlighted BRG's commitment to its motto: It's Better @ BRG, lauding the firm's exceptional staff and client retention, and fourth consecutive year of double-digit revenue growth.
  • The PRWeek awards are one of the industry's highest honors, representing leadership, innovation and exceptional results that set nominees apart in the fields of corporate, agency, nonprofit, and education.

The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On

Retrieved on: 
Monday, March 11, 2024
Connect the dots, Health, Disability, Organization, Learning, Health equity, CKD, Risk, Education, Patient, Black, Dots, Death, American Diabetes Association, Chronic condition, RDS, Chronic kidney disease, DaVita Inc.

DENVER, March 11, 2024 /PRNewswire/ -- Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD). The kick-off for this expanded effort coincides with National Kidney Month, a time when both organizations bolster efforts to increase kidney health awareness and education.

Key Points: 
  • Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National Kidney Month
    DENVER, March 11, 2024 /PRNewswire/ -- Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD).
  • Chronic disease is the leading cause of death and disability in the United States.
  • [1] More than 38 million Americans are living with diabetes, and approximately one in three American adults with diabetes has CKD.
  • On March 26, DaVita dietitians will join the ADA for a live cooking class featuring a tasty diabetes- and kidney-friendly meal.

Treatment.com AI Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Bangladesh Technical Education Board, GLM, Diabetes, American Diabetes Association, Sunburst, AI, UMN, American Academy, OTC, Physician, News, Growth, Royal college, Geography, NOW, Advertising, CAD, University, Partner, Engineering, Patient, Family medicine, Primary care, Acceleration, Diagnosis, Machine learning, Medical school, Risk, Publication

VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update. Treatment has been working diligently to continue its acceleration into the US market. A few key milestones the Company has accomplished are as follows:

Key Points: 
  • Treatment Provides Platform to Support Healthcare in Nairobi, Kenya
    VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update.
  • Dr. Kevin Peterson is the Founder and Chief Medical Officer of Treatment.com AI Inc.
  • Whilst utilizing AI, the GLM has been curated & evaluated by 150+ physicians globally to be correct, reliable and accurate.
  • Treatment’s platform provides clinical decision support to assist the healthcare workers in making an accurate diagnosis.